| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenue | 756,217 | - | 1,136,287 | 1,100,152 |
| Cost of revenue | 815,871 | - | 1,272,348 | 1,619,801 |
| Gross loss | -59,654 | - | -136,061 | -519,649 |
| Selling expenses | 78,041 | - | 87,111 | 134,603 |
| General and administrative expenses | 424,827 | - | 507,182 | 345,051 |
| Research and development expenses | 40,321 | - | 29,587 | 87,610 |
| Credit losses (reversal of allowance for credit losses) | 25,302 | - | -1,323 | -1,656 |
| Total operating expenses | 568,491 | - | 622,557 | 565,608 |
| Loss from operations | -628,145 | - | -758,618 | -1,085,257 |
| Research and development subsidy | 415 | - | - | - |
| Interest income | 294 | - | 1,074 | - |
| Interest expense, nonoperating | - | - | - | 34,114 |
| Interest expense | 24,046 | - | 28,028 | - |
| Investment income, interest | - | - | - | 1,460 |
| Income tax expense | - | 0 | - | - |
| Net other (expense) income | -23,337 | - | -26,954 | - |
| Loss before income taxes | -651,482 | -528,367 | -785,572 | -1,117,911 |
| Net loss | -651,482 | -528,367 | -785,572 | -1,117,911 |
| Other comprehensive income - foreign currency translation adjustment | 57,335 | 20,263 | 7,516 | 137,638 |
| Comprehensive loss | -594,147 | -508,104 | -778,056 | -980,273 |
| Loss per share basic (in dollars per share) | -0.17 | -0.16 | -0.24 | -0.06 |
| Loss per share diluted (in dollars per share) | -0.17 | -0.16 | -0.24 | -0.06 |
| Weighted average shares outstanding (in shares) | 3,874,085 | 3,262,002 | 3,261,911 | 17,306,689 |
CHINA PHARMA HOLDINGS, INC. (CPHI)
CHINA PHARMA HOLDINGS, INC. (CPHI)